ADC Therapeutics highlights ZYNLONTA growth opportunity in corporate presentation
ADCT•Safety findings
- Safety profile mixed: Grade 5 TEAEs 13.2% vs 4.6%; hematologic Grade ≥3 TEAEs higher with R-GemOx.
LOTIS-5 Phase 3 results
- LOTIS-5 Phase 3 met its primary PFS endpoint: HR 0.73, p 0.0084; median PFS 6.14 months vs 4.73 months.
- Complete responses improved to 40% from 27%; 24-month CR durability 48.5% vs 16.7%.
- Overall survival showed no detriment: HR 0.96; median OS 12.19 months vs 12.16 months.
ZYNLONTA growth ambitions and market opportunity
ADC Therapeutics highlighted ZYNLONTA growth ambitions, targeting a multi-billion-dollar U.S. opportunity across 2L+ DLBCL and 2L+ indolent lymphomas.
